• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem inks distro deal in Italy for insulin pump

April 9, 2018 By Sarah Faulkner

Tandem DiabetesTandem Diabetes Care (NSDQ:TNDM) has signed a distribution deal with Movi SpA to commercialize Tandem’s t:slim X2 insulin pump in Italy.

The San Diego, Calif.-based company said today that Movi is slated to run sales, marketing and customer training for Tandem’s products in Italy, according to the terms of the agreement.

“Partnering with experienced insulin pump distributors is key to our international commercialization strategy as we work to expand available insulin pump options for patients and healthcare providers worldwide,” president & CEO Kim Blickenstaff said in prepared remarks. “Movi shares in our passion to help improve the lives of people with diabetes, and we look forward to working with them to bring the t:slim X2 Insulin Pump to the diabetes communities in Italy.”

“We are proud to offer the t:slim X2 Insulin Pump to people with Type I diabetes and healthcare providers in Italy, to provide an innovative and reliable alternative to the current market option,” Movi’s president, Enrico Piero Bassani, added. “We thank Tandem Diabetes Care for trusting us as their distributor for Italy, and we look forward to bringing the benefits of Tandem’s products to the patients and clinics that we service.”

Movi also distributes Valeritas‘ (NSDQ:VLRX) V-Go insulin delivery device in Italy.

Last month, Tandem topped expectations on Wall Street with its fourth quarter and full-year results. The company reeled in its losses in Q4, posting a net loss of -$11.4 million on sales of $40.3 million for the 3 months ended Dec. 31, for sales growth of 39% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -$1.23, ahead of consensus on The Street, where analysts were looking for sales of $38 million.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Distribution, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS